Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Continuous glucose monitoring (CGM) can benefit a much broader group of patients with type 2 diabetes than those for whom it is currently recommended, and who have access to it, new research suggests.
The data come from two studies, both published online June 2 in JAMA.
One study, a randomized clinical trial, showed that CGM use resulted in significantly improved A1c at 8 months among adults with type 2 diabetes taking long-acting insulin alone without premeal insulin. The study will also be presented during the virtual 14th International Conference on Advanced Technologies & Treatments for Diabetes.
Currently, CGM use in type 2 diabetes is only strongly recommended for those taking both long-acting basal insulin and short-acting pre-meal bolus insulin.
"Until now we were unsure of the benefit [of CGM] for people with type 2 diabetes who were on less complicated background insulin regimens," said the study's lead author, Thomas Martens, MD, of the International Diabetes Center, Minneapolis, Minnesota, in a press release.
These data expand "the number of people who could benefit from these devices, and points to a possible future in which CGMs are common in primary care clinics across the US."
www.medscape.com
The data come from two studies, both published online June 2 in JAMA.
One study, a randomized clinical trial, showed that CGM use resulted in significantly improved A1c at 8 months among adults with type 2 diabetes taking long-acting insulin alone without premeal insulin. The study will also be presented during the virtual 14th International Conference on Advanced Technologies & Treatments for Diabetes.
Currently, CGM use in type 2 diabetes is only strongly recommended for those taking both long-acting basal insulin and short-acting pre-meal bolus insulin.
"Until now we were unsure of the benefit [of CGM] for people with type 2 diabetes who were on less complicated background insulin regimens," said the study's lead author, Thomas Martens, MD, of the International Diabetes Center, Minneapolis, Minnesota, in a press release.
These data expand "the number of people who could benefit from these devices, and points to a possible future in which CGMs are common in primary care clinics across the US."
Wider Use of CGM May Benefit People With Type 2 Diabetes
'The time has come to broaden access to CGM for patients with type 2 diabetes,' say editorialists commenting on two studies they say provide 'a powerful narrative' for this cause.
www.medscape.com